S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:EYENEyenovia Stock Price, Forecast & News

$3.57
+0.02 (+0.56 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.52
Now: $3.57
$3.57
50-Day Range
$2.61
MA: $3.13
$4.24
52-Week Range
$1.11
Now: $3.57
$5.06
Volume1,520 shs
Average Volume241,675 shs
Market Capitalization$70.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Read More
Eyenovia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share

Profitability

Net Income$-21,160,000.00

Miscellaneous

EmployeesN/A
Market Cap$70.61 million
Next Earnings Date8/12/2020 (Confirmed)
OptionableNot Optionable
$3.57
+0.02 (+0.56 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

How has Eyenovia's stock been impacted by COVID-19 (Coronavirus)?

Eyenovia's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYEN stock has increased by 23.1% and is now trading at $3.57.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Eyenovia?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eyenovia
.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Eyenovia
.

How can I listen to Eyenovia's earnings call?

Eyenovia will be holding an earnings conference call on Wednesday, August 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01.
View Eyenovia's earnings history
.

What price target have analysts set for EYEN?

4 Wall Street analysts have issued 1-year price targets for Eyenovia's shares. Their forecasts range from $6.00 to $19.00. On average, they expect Eyenovia's share price to reach $12.50 in the next year. This suggests a possible upside of 250.1% from the stock's current price.
View analysts' price targets for Eyenovia
.

Has Eyenovia been receiving favorable news coverage?

News stories about EYEN stock have trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyenovia earned a news impact score of -4.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Eyenovia
.

Are investors shorting Eyenovia?

Eyenovia saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 96,700 shares, a decrease of 6.2% from the July 15th total of 103,100 shares. Based on an average trading volume of 114,200 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the shares of the stock are short sold.
View Eyenovia's Current Options Chain
.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the following people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $3.57.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $70.61 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

What is Eyenovia's official website?

The official website for Eyenovia is www.eyenoviabio.com.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.